(07 April 2021) – The Commission is mobilising €123 million from Horizon Europe for urgent research into coronavirus variants.
This first emergency funding under Horizon Europe adds to a range of EU-funded research and innovation actions to fight the coronavirus and contributes to the Commission’s overall action to prevent, mitigate and respond to the impact of coronavirus variants, in line with the new European bio-defence preparedness plan HERA Incubator.
The Commission launched new calls that complement earlier actions to develop treatments and vaccines by organising and conducting clinical trials to advance the development of promising therapeutics and vaccines against SARS-CoV-2/COVID-19.
They will support the development of large scale, COVID-19 cohorts and networks beyond Europe’s borders, forging links with European initiatives, as well as reinforce the infrastructures needed to share data, expertise, research resources and expert services among researchers and research organisations.